Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
about
Reply to F. Tomao et al.Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.Talking about women's sexual health after cancer: Why is it so hard to move the needle?Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al.Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
P2860
Q33816570-252B44AF-69BD-4D6E-9DC1-37616AF0DA2AQ36413980-B90F04FA-2EF3-437C-898B-D04D9A91524AQ37130142-09879550-8D4E-4A39-B9FE-1E8244AE3FA5Q37547937-ABE77C8F-4B79-46A3-8902-5849A9067850Q38870541-EFDB1E6D-F529-41A3-9E71-626C61ED92A2Q38968531-63508144-C900-4B3F-9237-CD8D190048F9Q40061357-9A0474B5-264E-4BEE-A482-135C35375051Q47622460-66D00F8E-FD0A-473A-A192-B9E89F5AF2FAQ48124124-6577EF55-EBD3-41B4-BF6C-2EFF6A77A1C1Q49608951-437CC494-1E0F-4E72-9931-7463A73AC568Q53538428-6AF6DF98-3400-49F5-A265-4159B2004271Q54974390-6C27C115-2D80-4D6A-A13E-3FC79B2D131CQ59128489-012349BE-2DC2-4A52-AD5E-FF55C86762F8
P2860
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant Tamoxifen Plus Ovaria ...... ion of Ovarian Function Trial.
@en
type
label
Adjuvant Tamoxifen Plus Ovaria ...... ion of Ovarian Function Trial.
@en
prefLabel
Adjuvant Tamoxifen Plus Ovaria ...... ion of Ovarian Function Trial.
@en
P2093
P2860
P50
P356
P1476
Adjuvant Tamoxifen Plus Ovaria ...... sion of Ovarian Function Trial
@en
P2093
Alan S Coates
Antonia Perelló
Aron Goldhirsch
Carlo Tondini
Davide Lombardi
Gini F Fleming
Harold J Burstein
Jürg Bernhard
Karen N Price
Karin Ribi
P2860
P304
P356
10.1200/JCO.2015.64.8675
P407
P577
2016-03-28T00:00:00Z